Sensory polyneuropathy associated with paclitaxel-eluting coronary stent.
Paclitaxel is a microtubule-stabilizing chemotherapeutic agent used in ovarian and breast cancer; its principal adverse effect is sensory neuropathy. We describe the occurrence of sensory polyneuropathy after multiple paclitaxel-eluting stents in a patient who may have sub-clinical Sjogrens syndrome.
Srinivasan
Jayashri
J
Department of Neurology, Lahey Clinic, 41 Mall Road, Burlington, Massachusetts 01805, United States. jayashri_srinivasan@lahey.org
Jones
H Royden
HR
D000368:Aged; D000789:Angina, Unstable / Q000150:complications / Q000188:drug therapy* / Q000628:therapy; D000800:Angioplasty, Balloon; D023903:Coronary Restenosis / Q000517:prevention & control; D004198:Disease Susceptibility; D054855:Drug-Eluting Stents / Q000009:adverse effects*; D006801:Humans; D008297:Male; D009431:Neural Conduction; D017239:Paclitaxel / Q000008:administration & dosage / Q000009:adverse effects*; D010292:Paresthesia / Q000139:chemically induced; D011115:Polyneuropathies / Q000139:chemically induced*; D012008:Recurrence; D012678:Sensation Disorders / Q000139:chemically induced*; D012859:Sjogren's Syndrome / Q000150:complications
D017239:Paclitaxel